Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on September 15, 2021. The report discloses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel and compensation arrangements.
Material Changes
The Board of Directors increased its size to nine members and elected Martin H. Huber, M.D., effective immediately. Dr. Huber was designated as a Class II member serving until the 2024 annual meeting. No related person transactions were disclosed.
Compensation and Governance Details
- Cash Compensation: Dr. Huber will receive $40,000 in annual cash compensation, paid in quarterly installments.
- Equity Grant: An initial one-time option to purchase 35,000 shares of common stock was granted.
- Vesting Schedule: The option vests monthly at a rate of 1/36 over a three-year period, contingent on continued service.
- Future Eligibility: Dr. Huber is eligible for annual option awards subject to the Company's Non-Employee Director Compensation Policy.
- Expenses: The Company will reimburse travel expenses related to Board meetings.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 35,000 share option grant on potential dilution.
- Review the Company's Non-Employee Director Compensation Policy for details on future annual option awards.
- Confirm Dr. Huber's background and qualifications as disclosed in the accompanying press release (Exhibit 99.1).
- Check subsequent filings for any changes to the Board composition or compensation terms.